Dairy Choline Bioavailability
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age51-70
SponsorUniversity of Wisconsin, Madison
About this trial
The goal of this clinical trial is to find out if dairy is a good source of choline compared to eggs. The main questions it aims to answer are:
* How the body uses choline; and, * What effect WPPC has on choline metabolism.
Researchers will compare Whey Protein Phospholipid Concentrate (WPPC) to whole egg powder to see if WPPC is as effective as eggs.
Participants will drink a chocolate-flavored smoothie mixed with either WPPC or whole egg powder.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Ages between 51 and 70
Is currently post-menopausal (Post-menopausal is a term used to describe the time in a woman's life after she has gone through menopause. This usually happens between the ages of 45 and 55. Menopause is when a woman's menstrual periods stop permanently (at least 12 months))
Not allergic to the intervention foods and allergens that are related to the production of intervention foods (e.g. dairy products, egg, fish, peanut, shellfish, soy, tree nuts, wheat, crustaceans, gluten, mollusks, mustard, sesame seeds.)
Had stable body weight (± 5%) for the past 6 months
Disqualifiers
On weight loss/weight gain diets
Diagnosed with fat malabsorption
Undergoing weight loss surgery
Diagnosed with chronic kidney diseases
Trial design
Design model
Parallel
Treatments tested in this trial
WPPC
Dietary supplementA chocolate-flavored smoothie with WPPC added
Whole egg powder
Dietary supplementA chocolate-flavored smoothie with whole egg powder added
Treatment groups
24 Participants
are divided into 2 treatment groupsGroup A: Whey Protein Phospholipid Concentrate (WPPC)Experimental treatment 1 intervention
Group B: Pasteurized whole egg powderExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Change in circulating choline
Circulating choline will be measured by UHPLC-HRMS/MS
Time frame
Baseline to 10 daysSecondary outcomes
1
Change in co-factors in circulating choline
Co-factors in the circulation will be measured by ultrahigh performance liquid chromatography coupled with high resolution tandem mass spectrometry (UHPLC-HRMS/MS).
Time frame
Baseline to 10 days2
Change in high-sensitivity C-reactive protein (hs-CRP)
Safety biomarker Hs-CRP will be measured using immunoturbidimetry.
Time frame
Baseline to 10 days3
Change in circulating choline metabolites
Metabolites will be measured by UHPLC-HRMS/MS.
Time frame
Baseline to 10 days4
Change in 8-hydroxydeoxyguanosine
The safety biomarker 8-hydroxydeoxyguanosine (8-OHDG) will be measured using enzyme-linked immunosorbent assay (ELISA).
Time frame
Baseline to 10 daysSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov